TOKYO, Apr 02 (Pulse News Wire) – Medrx CO.,LTD. (4586.T) reported mixed results from its phase 2 proof-of-concept trial of Alto-101, a schizophrenia treatment developed in collaboration with US biotech firm Alto Neuroscience, Inc.
The study showed near-significant improvements in EEG theta band metrics (p=0.052) but did not achieve statistical significance overall. While there was no significant effect compared to placebo across cognitive measures, some trends indicated potential efficacy in certain EEG parameters and a nearly significant effect (n=83, d=0.34, p=0.052) in a related metric. A subgroup analysis also found nominal significance (d=0.44, p=0.03) in patients with more severe cognitive impairment. Additionally, the drug demonstrated good tolerability, with nausea and vomiting rates similar to those seen with placebo, suggesting potential to overcome tolerance barriers associated with PDE4 inhibitors.
However, high skin side effects at the application site were observed in both groups. Based on these findings, Alto plans to prioritize resources towards its lead pipeline candidate, Alto-207, while exploring strategic partnerships for further development of Alto-101. Medrx intends to conduct detailed analyses with Alto and consider formulation modifications moving forward. The impact on current earnings is expected to be minor.
🟢 Confidence: High AI-translated content.